Announcements
| Date | Title | |
|---|---|---|
| 9 February 2012 | Recordati: positive preliminary 2011 results. Sales +4.7%, EBIT +5.6%, net income +7.2% |
 |
| 31 January 2012 | Recordati: public disclosure compliance |
|
| 28 November 2011 | Recordati: 2012 Corporate events' calendar |
|
| 18 November 2011 | Recordati: update on the execution of the share buy-back program |
|
| 15 November 2011 | Directors' report and financial statements interim dividend |
|
| 15 November 2011 | Notice of payment 2011 interim dividend |
|
| 14 November 2011 | Recordati Board of Directors approves 2011 interim dividend of € 0.20 per share |
|
| 26 October 2011 | Notice of filing of financial report at 30 September 2011 |
|
| 25 October 2011 | Very good first nine months 2011 results. Sales +5.8%. Net income +5.8% Interim dividend distribution policy approved |
|
| 7 October 2011 | Recordati; update on the execution of the share buy-back program |
|
| 29 September 2011 | Recordati: update on the execution of the share buy-back program |
|
| 22 September 2011 | Recordati initiates share buy-back program |
|
| 14 September 2011 | Recordati finalizes its acquisition of Frik İlaç in Turkey |
|
| 27 July 2011 | Notice of filing of First Half 2011 financial report |
|
| 26 July 2011 | Recordati: very good first half 2011 results. Sales +6.6%. Net income +5.3% |
|
| 1 July 2011 | Recordati acquires Dr. Frik İlaç in Turkey |
|
| 31 May 2011 | Recordati: approval granted for the use of Carbaglu® in the treatment of organic acidaemias |
|
| 10 May 2011 | Recordati: public disclosure compliance |
|
| 7 May 2011 | Notice of filing of First quarter 2011 financial report |
|
| 6 May 2011 | Recordati: sales and income increase in the first quarter 2011. Three year business plan updated |
|
| 2 May 2011 | Recordati announces the first European launch of pitavastain |
|
| 27 April 2011 | Recordati: to meet with the financial community and specialized press in Milan |
|
| 14 April 2011 | Notice of dividend payment for the financial year 2010 |
|
| 13 April 2011 | Recordati: shareholders approve the 2010 accounts, dividend € 0.275 per share |
|
| 24 March 2011 | Recordati: update on the execution of the share buy-back program |
|
| 23 March 2011 | Recordati: publication of the lists of candidates for the appointment of the Company's Directors of the Statutory Auditors |
|
| 20 March 2011 | Recordati: information pursuant to art. 144-octies, paragraph 2 of issuers' regulations |
|
| 18 March 2011 | Recordati: update on the executionof the share buy-back program |
|
| 14 March 2011 | Recordati: public disclosure compliance |
|
| 10 March 2011 | Recordati: publication of 2010 Annual Report and Annual Report on Corporate Governance |
|
| 10 March 2011 | Recordati: update on the execution of the share buy-back program |
|
| 9 March 2011 | Recordati: 2010 accounts approved by the Board. Net income € 108.6 million. Dividend per share € 0.275 |
|
| 3 March 2011 | Recordati: update on the execution of the share buy-back program |
|
| 2 March 2011 | Recordati: notice to convene an ordinary and extraordinary meeting of the shareholders |
|
| 23 February 2011 | Recordati: update on the execution of the share buy back program |
|
| 15 February 2011 | Recordati initiates share buy-back program |
|
| 10 February 2011 | Recordati: change to the corporate events calendar 2011 |
|
| 9 February 2011 | Recordati: preliminary full year 2010 results: revenues € 728.1 M. net income € 108.6 M. Profitability margins in line with 2009 |
|
| 19 January 2011 | Recordati acquires Procto-Glyvenol® for the Central and Eastern European markets |
|
| 23 December 2010 | Recordati signs co-marketing agreement with Merck Serono in France for pitavastatin |
|
| 23 December 2010 | Recordati in-licenses Cardicor® in Italy from Merck KGaA |
|
| 16 December 2010 | Recordati and Nymox Pharmaceutical Corporation announce European licensing agreement for NX-1207 |
|
| 15 December 2010 | Recordati: public disclosure compliance |
|
| 28 October 2010 | Recordati: minutes of the Board meeting published which amended the by-laws to comply with new regulations on shareholder rights |
|
| 26 October 2010 | Notice of filing of financial report at 30 September 2010 |
|
| 26 October 2010 | Recordati: positive first nine months 2010 results, EBIT and net income increase |
|
| 28 August 2010 | The sixth edition of the Arrigo Recordati International Prize for Scientific Research issues the Call for Nominations |
|
| 29 July 2010 | Notice of filing of First Half 2010 financial report |
|
| 28 July 2010 | Recordati: positive first half 2010 results, EBIT and net income increase |
|
| 15 July 2010 | Recordati: positive conclusion to the Decentralized Procedure for the approval in Europe of pitavastatin (Livazo®) |
|
| 8 June 2010 | Recordati enters the Romanian market |
|
| 7 May 2010 | Recordati signs an agreement with Zambon for the co-marketing of silodosin in France |
|
| 6 May 2010 | Recordati: positive first quarter 2010 results, sales and income increase. Three year business plan updated |
|
| 27 April 2010 | Recordati to meet with the financial community and specialized press in Milan |
|
| 13 April 2010 | Dividend payment for the financial year 2009 |
|
| 13 April 2010 | Recordati: shareholders approve the 2009 accounts. Dividend € 0.275 per share (+10.0%) |
|
| 7 April 2010 | Recordati signs co-marketing agreement with Esteve in Spain for pitavastatin |
|
| 26 March 2010 | Recordati: documents of the annual Shareholders'meeting of 13th April 2010 (1st call) and 16th April 2010 (2nd call) |
|
| 19 March 2010 | Recordati: Carbaglu® approved by the FDA for use in the U.S.A. |
|
| 15 March 2010 | Recordati and Leespharm announce partnership for Zanidip® in China |
|
| 11 March 2010 | Notice of Annual Shareholders' Meeting to be held on 13 April 2010 |
|
| 5 March 2010 | Recordati: 2009 accounts approved by the board. Net income € 110.6 million. Dividend per share € 0.275 (+10%) |
|
| 11 February 2010 | Recordati: preliminary full year 2009 results in line with targets: revenues +8.4%, net income +10.1% |
|
| 3 February 2010 | Recordati: silodosin (Urorec®/Silodyx™) approved by the European Commission for the treatment of the signs and symptoms of BPH |
|
| 20 November 2009 | Recordati: EMEA/CHMP adopts a positive opinion for silodosin (brands Urorec® and Silodyx™) |
|
| 27 October 2009 | Recordati: positive first nine months 2009 results, sales and income increase |
|
| 29 July 2009 | Recordati signs a license agreement with Pharmaplan for silodosin in South Africa |
|
| 29 July 2009 | Recordati signs an agreement with Nycomed for the co-marketing of silodosin in Italy |
|
| 28 July 2009 | Recordati: positive first half 2009 results, sales and income increase |
|
| 14 July 2009 | Recordati announces revenues up 8.9% in the first half 2009 |
|
| 13 July 2009 | Recordati obtains TransAct LAT® license from Amdipharm |
|
| 6 May 2009 | Recordati: positive first quarter 2009 results |
|
| 15 Aprile 2009 | Recordati launches Zanextra® in France |
|
| 7 April 2009 | Recordati: shareholders approve the 2008 accounts. Dividend € 0,25 per share (+16.3%) |
|
| 3 April 2009 | Recordati signs co-marketing agreement with Almirall in Spain for silodosin |
|
| 3 March 2009 | Recordati: 2008 accounts approved by the board. Net income +18.3%. Dividend per share € 0.25 |
|
| 11 February 2009 | Recordati: preliminary full year 2008 results in line with targets: revenues +9.7%, net income +18.3% |
|
| 19 January 2009 | Recordati acquires Herbaco-Bofarma in the Czech Republic |
|
To view PDFs you need the Adobe Acrobat Reader. This program is available free of charge from the Adobe website.
